EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications

Stephen Ludgate iD, Sarah C Brennan iD, James McNeil iD, Venessa Hm Tsang iD, Bruce G Robinson, Lyndal Tacon, Roderick J Clifton-Bligh iD, Matti L Gild iD

Endocrine-Related Cancer · 01.07.2026 · 33 (7)

DOI: 10.1530/erc-25-0516 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, online erschienen am 11.06.2026. Verfasst von Stephen Ludgate und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital , St. Leonards, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Endocrine Gland Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary endocrine neoplastic syndromes require structured, lifelong surveillance owing to their multisystem involvement, variable penetrance, and high risk of multifocal and metastatic disease. Functional imaging (FI) is now integral to their management, providing molecular characterisation that complements conventional anatomical modalities and frequently enables earlier or more specific lesion detection. This review summarises current FI approaches across major hereditary syndromes, including multiple endocrine neoplasia types 1–4, von Hippel–Lindau disease, and hereditary paraganglioma–phaeochromocytoma syndromes with emphasis on radiotracer selection, genotype–phenotype correlations and implications for clinical practice. The performance and biological rationale for established radiotracers, including 18F-FDG, 68Ga-DOTATATE, 18F-DOPA, and choline-based PET agents and emerging probes, is described. Increasing evidence supports genotype-directed imaging algorithms, particularly in HPPSs, where molecular subtype predicts tracer avidity and guides theranostic strategies. The expanding theranostic framework, anchored in somatostatin receptors and norepinephrine transporter-directed radiopharmaceuticals, has reshaped treatment pathways for advanced and metastatic disease. Implementation challenges persist, including variable global access, high costs, workforce limitations, and concerns regarding cumulative radiation exposure during decades of surveillance. Technical constraints related to spatial resolution, partial-volume effects, and motion artefact continue to limit the sensitivity of small-lesion detection. Emerging approaches incorporating radiomics and artificial intelligence offer opportunities to enhance lesion characterisation, infer genetic subtype, and improve prognostication. Advancing FI in hereditary endocrine neoplasia will require genetically informed surveillance protocols, harmonised imaging standards, and equitable access to specialised modalities. Collectively, these developments have the potential to refine risk stratification, improve treatment selection, and optimise long-term outcomes for individuals with hereditary endocrine malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endocrine Gland NeoplasmsNeoplastic Syndromes, HereditaryHumansMultiple Endocrine Neoplasia

Stichwörter der Autor:innen

functional imaginghereditary endocrine cancer syndromesmultiple endocrine neoplasiasphaeochromocytomavon Hippel–Lindau disease

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital , St. Leonards, Sydney, New South Wales, Australia.
  • School of Medicine, University of Dublin Trinity College , Dublin, Ireland.
  • School of Life & Environmental Sciences, The University of Sydney , Sydney, Australia.
  • Adelaide Medical School, University of Adelaide , Adelaide, South Australia, Australia.
  • Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, South Australia, Australia.
  • Department of Nuclear Medicine, Royal Adelaide Hospital , Adelaide, South Australia, Australia.

ORCID-Profile: Stephen Ludgate, Sarah C Brennan, James McNeil, Venessa Hm Tsang, Roderick J Clifton-Bligh, Matti L Gild

Zitieren

APA

Ludgate, S., Brennan, S. C., McNeil, J., Tsang, V. H., Robinson, B. G., Tacon, L., Clifton-Bligh, R. J., & Gild, M. L. (2026). FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications. Endocrine-Related Cancer, 33(7). https://doi.org/10.1530/erc-25-0516

Vancouver

Ludgate S, Brennan SC, McNeil J, Tsang VH, Robinson BG, Tacon L, et al. FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications. Endocrine-Related Cancer. 2026;33(7). doi:10.1530/erc-25-0516

BibTeX
@article{Ludgate2026,
  author = {Ludgate, Stephen and Brennan, Sarah C and McNeil, James and Tsang, Venessa Hm and Robinson, Bruce G and Tacon, Lyndal and Clifton-Bligh, Roderick J and Gild, Matti L},
  title = {FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1530/erc-25-0516}
}
Kostenlos starten →